Mosunetuzumab
Mosunetuzumab
Monoclonal antibody
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma.[2][3][5] It bispecifically binds CD20 and CD3 to engage T-cells.[2][3] It was developed by Genentech.[6]
The most common adverse reactions (≥20%) include cytokine release syndrome, fatigue, rash, pyrexia, and headache.[3][4] The most common grade 3 to 4 laboratory abnormalities (≥10%) include decreased lymphocyte count, decreased phosphate, increased glucose, decreased neutrophil count, increased uric acid, decreased white blood cell count, decreased hemoglobin, and decreased platelets.[3][4]
Mosunetuzumab was approved for medical use in the European Union in June 2022,[4] and in the United States in December 2022.[3][7] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[8][9]